【Product for Licensing】The Phase II Small Molecule targeting IL-17 & IL-4Ra solves unmet medical needs in Psoriasis and Atopic Dermatitis

Project ID：BP-20240618-OR-060

Product Brief Summary

• Product Name: 
• Modality: Small Molecule
• Target: IL-17 & IL-4Ra
• Therapeutic Area: Immunology- Psoriasis, Atopic Dermatitis
• Current Stage: China Phase II
• Rights Available: China/Global Right
• Collaboration Mode: License out

Mechanism of action

• The product decreased IL-1β、IL-6、IL-8、MCP-1、ICAM-1 in HaCaT cells stimulated by TNF-/IFN-γ
• The product decreased the release of β-hexosaminidase and histamine in BMMCs stimulated by IgE
• The product decreased protein levels of IL-4、TNF-α and IL-13 in BMMCs stimulated by IgE
• The product decreased the percentage of IL-17A-producing T cells in murine spleen cells stimulated by Con A.
• The product cream suppressed IL-17 production and proinflammatory cytokines in the psoriasis-like skin inflammation in IMQ-induced murine model.
• The effect of blockade IL-17 both in vitro and in vivo can mainly explain why the product has potential to apply on psoriasis.
• The product can bind to IL-4Rα, affect downstream pathways, and improve atopic dermatitis like symptoms.

Clinical needs for Psoriasis

• Demand for fast removal of skin lesion
• Long-term treatment and easy to relapse
• Worry about medicine safety
• Conventional therapies not enough

Treatment direction for Psoriasis

• Rapid removal of lesions
• Treatment compliance
• Good safety
• Control of recurrence

Clinical needs for Atopic Dermatitis

• Long-term treatment and easy to relapse
• Intense itch
• A large number of adolescent patients
• Worry about medicine safety
• Conventional therapies not enough

Treatment direction for Atopic Dermatitis

• Itch control
• Treatment compliance
• Good safety
• Control of recurrence

The features of the candidate for psoriasis

• Inhibition of IL-17—a pathogenic factor of psoriasis and improvement of skin lesion with the effect not weaker than glucocorticoid
• Decrease of psoriasis-like symptoms in IMQ-induced relapse murine model
• Good safety of topical application on skin with the PK characteristics showing high AUC in skin tissue but low in system to meet the demand of long-term treatment on psoriasis patients
• Focusing on the First-line therapy on mild to moderate psoriasis and combination therapy or sequential therapy on moderate to severe psoriasis

The features of the candidate for Atopic Dermatitis

• Inhibition of IL-4—a pathogenic factor of atopic dermatitis and improvement of skin lesion
• Suppression of histamine release and intense itch
• Good safety of topical application on skin with the PK characteristics showing high AUC in skin tissue but low in system to meet the demand of long-term treatment on Atopic Dermatitis patients
• Focusing on mild to moderate atopic dermatitis and combination therapy or sequential therapy on moderate to severe atopic dermatitis

Pharmaceutical effects on Psoriasis

• The product attenuated the psoriasis-like symptoms, including erythema and scaling
• The product relieved the pathological features of psoriasis-like skin inflammation in IMQ-induced murine model.
• The product Cream decreased psoriasis-like symptoms in IMQ-induced relapse murine model.
• The product Cream decreased PASI score, and total pathological score in lesion skin.

Pharmaceutical effects on Atopic Dermatitis

• The product Cream attenuated the AD-like symptoms in MC903-induced murine model, including dermatitis score, ear thickening, epidermal and dermal hyperplasia
• The product decreased the number of mast cells in ears, and IgE protein level in serum in mice.
• The product decreased proinflammatory cytokines, like IL-4, IL-13 and TSLP in lesion ears.

Contact

• If interested, please contact DrugTimes BD Team at BD@drugtimes.cn. Many thanks!